Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2013-08-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT01581931
- Locations
- 🇩🇪
1288.20.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients
- Conditions
- Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
- Interventions
- First Posted Date
- 2012-04-18
- Last Posted Date
- 2018-05-25
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 90
- Registration Number
- NCT01579812
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.
- Conditions
- Carcinoma, Non-Small-Cell LungLung Adenocarcinoma
- Interventions
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 25
- Registration Number
- NCT01578551
- Locations
- 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
🇺🇸Johns Hopkins University SKCCC, Baltimore, Maryland, United States
A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes)
- First Posted Date
- 2012-04-10
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 7
- Registration Number
- NCT01573949
- Locations
- 🇺🇸
Ahmanson-UCLA Cardiomyopathy Center, Los Angeles, California, United States
Efficacy of Metformin and Diane-35 on PCOS Patients,a Randomized, Controlled, Prospective Clinical Trial
- Conditions
- Polycystic Ovary SyndromeInsulin Resistance
- Interventions
- First Posted Date
- 2012-04-09
- Last Posted Date
- 2013-12-30
- Lead Sponsor
- Chongqing Medical University
- Target Recruit Count
- 40
- Registration Number
- NCT01573377
- Locations
- 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Metformin Plus Neoadjuvant Chemotherapy in Breast Cancer
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2012-03-30
- Lead Sponsor
- Instituto Nacional de Cancerologia de Mexico
- Target Recruit Count
- 60
- Registration Number
- NCT01566799
- Locations
- 🇲🇽
Instituto Nacional Cancerologi, Mexico, Distrito Federal, Mexico
Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy
- Conditions
- Diabetes Mellitus Type II
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2012-03-28
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 44
- Registration Number
- NCT01565096
- Locations
- 🇩🇪
ikfe GmbH, Mainz, Germany
A Comparison Between Two Oral Hypoglycemics - Metformin and Glybenclamide for the Treatment of Gestational Diabetes Mellitus
- Conditions
- Gestational Diabetes Mellitus
- Interventions
- First Posted Date
- 2012-03-26
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- HaEmek Medical Center, Israel
- Target Recruit Count
- 108
- Registration Number
- NCT01563120
- Locations
- 🇮🇱
Dep. OB/GYN, Emek Medical Center, Afula, Israel
Study of Metformin With Simvastatin for Men With Prostate Carcinoma
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2015-07-22
- Lead Sponsor
- Nicholas Mitsiades
- Registration Number
- NCT01561482
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸Michael E. Debakey Veterans Affairs Medical Center, Houston, Texas, United States
🇺🇸Ben Taub General Hospital, Houston, Texas, United States
A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2012-03-19
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 25
- Registration Number
- NCT01557504
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.